ナノバイオテクノロジーの世界市場 - 2025年～2033年

世界のナノバイオテクノロジー市場は、2024年に1,373億米ドルに達し、2033年には2,705億6,000万米ドルに達すると予測され、予測期間2025年～2033年のCAGRは8.1%で成長すると予測されています。

ナノバイオテクノロジーとは、ドラッグデリバリー、診断、バイオセンシングを含む様々な用途のために、生体系にナノスケールの材料とプロセスを統合することです。これには、分子レベルで生物学的プロセスと相互作用できる機器やシステムの開発が含まれ、その結果、生物学的研究と医療応用における理解と能力が向上します。ナノスケールの材料と相互作用し、より大きな材料とは異なる特別な特徴を利用することも含まれます。ナノバイオテクノロジーは、生物学、化学、物理学、工学、医学の概念を融合させ、新しいアプリケーションを開発します。

ナノバイオテクノロジーの採用の増加と技術的進歩が、予測期間中の市場を動かす要因です。例えば、2024年9月、研究用および体外診断（IVD）市場向けに新しいタンパク質を生成するためにAIを使用するライフサイエンス企業であるMonod Bio社は、わずか15分で結果を提供する迅速バイオセンサーアッセイプラットフォームであるNovoLISAの発売を発表し、RUO設定でしばしば使用されるELISAアッセイプラットフォームなどの代替法と比較して、結果が出るまでの時間を大幅に短縮しました。

市場力学：

促進要因と抑制要因

ナノバイオテクノロジーの採用と技術進歩の増加

ナノバイオテクノロジーの採用増加と技術的進歩は、世界のナノバイオテクノロジー市場の成長における重要な要因になると予想されます。ナノテクノロジーが多くの分野、特にヘルスケアを変革する可能性を産業界が認識するにつれ、革新的なアプローチへの需要が急増しています。この動向は、研究開発（R&D）への多額の投資によって推進されており、複雑な医療上の懸念に対処できる新しいナノ材料やアプリケーションの開発に不可欠です。ナノテクノロジーをバイオテクノロジーに統合することで、治療効果と精度が向上し、患者の転帰が改善されます。

さらに、学術機関、産業組織、政府機関の連携により、イノベーションを受け入れる環境が整いつつあります。こうした協力関係は、知識の移転とリソースの共有を促進し、ナノバイオテクノロジー製品の開発と商業化を加速します。さらに、この分野の研究を促進するための政府の融資措置が、開発の可能性を後押ししています。その結果、ナノバイオテクノロジー分野の継続的な進歩を支える強力なエコシステムが構築されつつあります。

例えば、2024年1月、オハイオ州コロンバスにあるバイオテクノロジー企業DNAナノボッツは、プレシード資金調達ラウンドを完了したばかりで、この資金はバイオファーマパートナープログラムの開発に使用されます。DNAナノボッツ社は、抗体を標的としたDNAナノ粒子を用いて、低分子化学物質、ペプチド、抗体、核酸、免疫療法など、さまざまな種類の治療用ペイロードの送達を最適化します。DNAナノボッツ社は、その事業拡大と提携イニシアチブを支援するため、オハイオ州立大学からDNAナノ構造技術のポートフォリオをライセンス供与されています。

2024年2月、シドニー大学は高性能科学機器のトップメーカーであるブルカー社と、精密医療とナノ医療の推進を目的とした5年間の重要な調査パートナーシップを締結しました。この提携により、同大学の遺伝子治療、ナノメディシン、病気の早期発見・治療に関する専門知識の向上が期待されます。同大学は、この提携の一環として、ブルカー社から先進的な原子間力顕微鏡を2台購入します。これらの最先端ツールは、生きた生物学的サンプルを高解像度で画像化するために作られ、これにより科学者は細胞のつながりを測定し、動的な化学プロセスを見ることができます。これらの顕微鏡の設置は、大学の前臨床および生物医学研究イニシアチブをサポートすることが期待されています。

厳しい規制要件

厳しい規制要件などの要因が、世界のナノバイオテクノロジー市場を阻害すると予想されています。主な課題の一つは、ナノテクノロジーを包含する規制の枠組みです。ナノ粒子の安全性や起こりうる副作用に関する懸念があるため、欧州医薬品庁（EMA）や米国食品医薬品局（FDA）のような規制機関は、ナノテクノロジーに基づく製品の承認をためらっています。承認プロセスは、特にナノテクノロジー用に設計された統一法がないために難しくなっており、これが新技術のリリースを遅らせる原因となっています。組織は複雑な規則を遵守しなければならないが、その規則では、ナノ粒子が環境や人体に与える長期的な影響について、綿密な調査や情報が頻繁に求められます。これにより、特に徹底的な安全性評価を実施する手段を持たない中小企業にとっては、成長のための時間と費用が大幅に増加する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
  • ナノバイオテクノロジーの採用と技術の進歩の増加
  • 抑制要因
  • 厳格な規制要件
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 償還分析
• 特許分析
• SWOT分析
• DMIの見解

第6章 ナノセンサー別

• 光学ナノセンサー
• 化学ナノセンサー
• 物理ナノセンサー
• バイオセンサー
• その他

第7章 ナノデバイス別

• ナノマニピュレーター
• ナノメカニクス試験装置
• ナノスケール赤外線分光計
• その他

第8章 用途別

• ドラッグデリバリー
• 診断
• 画像
• 遺伝子送達
• 組織工学
• その他

第9章 エンドユーザー別

• 製薬・バイオ医薬品企業
• 学術調査室
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• Johnson & Johnson Services, Inc.
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Abbott
• Novartis AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• Pfizer Inc.
• Nanonics Imaging Ltd.
• Bruker

第13章 付録

The global nano-biotechnology market reached US$ 137.3 billion in 2024 and is expected to reach US$ 270.56 billion by 2033, growing at a CAGR of 8.1% during the forecast period 2025-2033.

Nanobiotechnology is the integration of nanoscale materials and processes in biological systems for a variety of applications, including drug delivery, diagnostics, and biosensing. It includes the development of instruments and systems that can interact with biological processes at the molecular level, hence increasing the understanding and capacities in biological research and medical applications. It involves interacting with nanoscale materials to make use of special features that set them apart from larger materials. Nanobiotechnology blends concepts from biology, chemistry, physics, engineering, and medicine to develop novel applications.

The increasing adoption and technological advancements of nanobiotechnology are the driving factors that drive the market over the forecast period. For instance, In September 2024, Monod Bio, a life sciences company using AI to generate new proteins for the research use and in vitro diagnostics (IVD) markets, announced the launch of the NovoLISA, a rapid biosensor assay platform that delivers results in just 15 minutes, drastically reducing the time to result when compared with alternative methods, such as the ELISA assay platform often used in RUO settings.

Market Dynamics: Drivers & Restraints

Increasing adoption and technological advancements of nanobiotechnology

The increasing adoption and technological advancements of nanobiotechnology are expected to be a significant factor in the growth of the global nano-biotechnology market. As industries recognize nanotechnology's potential to transform numerous areas, particularly healthcare, the demand for innovative approaches upsurges. This trend is being driven by considerable investments in research and development (R&D), which are critical for developing new nanomaterials and applications that can address complicated medical concerns. Integrating nanotechnology into biotechnology improves therapeutic efficacy and precision, resulting in better patient outcomes.

Furthermore, collaborations among academic institutions, industrial organizations, and government agencies are developing an environment receptive to innovation. These collaborations promote knowledge transfer and resource sharing, accelerating the development and commercialization of nanobiotechnology products. Furthermore, government financing measures to promote research in this subject are boosting development potential. As a result, a strong ecosystem is building to support continuous progress in the field of nanobiotechnology.

For instance, in January 2024, DNA Nanobots, a biotechnology company located in Columbus, Ohio, recently wrapped up its pre-seed funding round, which will be used to develop its BioPharma Partner Program. DNA Nanobots use antibody-targeted DNA nanoparticles to optimize the delivery of various kinds of therapeutic payloads, including small chemicals, peptides, antibodies, nucleic acids, and immunotherapies. To support its expansion and partnership initiatives, DNA Nanobots has licensed a portfolio of DNA nanostructure technology from The Ohio State University.

In February 2024, The University of Sydney entered into a significant five-year research partnership with Bruker, a leading manufacturer of high-performance scientific instruments, to advance precision medicine and nanomedicine. The university's expertise in gene treatments, nanomedicine, and early disease detection and treatment is expected to improve as a result of this partnership. The University will purchase two advanced atomic force microscopes from Bruker as part of this collaboration; they will be the first of their kind in Australia. These cutting-edge tools are made to image living biological samples at high resolution, which allows scientists to measure cellular connections and see dynamic chemical processes. The installation of these microscopes is anticipated to support the university's preclinical and biomedical research initiatives.

Stringent regulatory requirements

Factors such as stringent regulatory requirements are expected to hamper the global nano-biotechnology market. One of the primary challenges is the regulatory framework that encompasses nanotechnology. Because of concerns regarding the safety and possible adverse effects of nanoparticles, regulatory bodies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) are hesitant to approve products based on nanotechnology. The approval process is made more difficult by the absence of uniform laws designed especially for nanotechnology, which causes delays in the release of new technologies. Organizations have to comply with a complicated set of rules that frequently call for in-depth research and information on the long-term impacts of nanoparticles on the environment and human health. Timelines and expenses for growth can be greatly accelerated by this, especially for smaller companies that do not have the means to carry out thorough safety assessments.

Segment Analysis

The global nano-biotechnology market is segmented based on nanosensor, nanodevice, application, end-user, and region.

Drug Delivery segment is expected to dominate the global nano-biotechnology market share

The drug delivery segment is anticipated to dominate the global nano-biotechnology market owing to its transformative potential in enhancing therapeutic efficacy and precision. The demand for targeted therapies that can effectively deliver medications while reducing adverse effects is growing as the healthcare industry changes. Drug delivery systems based on nanotechnology encapsulate therapeutic chemicals in nanoscale materials, enabling controlled release and focused action at certain body locations. This ability is particularly essential in oncology, as targeted administration can enhance treatment results by delivering medications only to tumor cells, preventing needless exposure of healthy tissues. Several factors, such as the rising prevalence of chronic diseases and the demand for novel treatment approaches, are contributing to this growth.

For instance, in September 2024, Scientists at the University of Chicago Medicine Comprehensive Cancer Center developed a nanomedicine that efficiently targets cancer cells and improves the uptake and penetration of chemotherapy medications in tumor tissues. Strong anticancer effects with significant tumor growth suppression and high cure rates were identified by the study team when they assessed the therapy's antitumor effects in a variety of tumor types.

The effectiveness of traditional medication delivery techniques may be hampered by issues including inadequate solubility and bioavailability. By improving the stability and permeability of medications across biological barriers, nanotechnology, on the other hand, provides solutions that improve therapeutic efficacy. Pharmaceutical companies are becoming more aware of the potential of nanoparticles to improve solubility and enable targeted distribution, which leads to more research and development into treatments based on nanoparticles.

For instance, in May 2024, Research led by the University of Sydney and the Sydney Local Health District developed a new type of oral insulin based on nanotechnology. In the future, it could offer the 75 million people worldwide who use insulin for diabetes a more effective and needle-free alternative. A nanoscale substance that is 1/10,000th the width of a human hair is used in the new oral insulin. The substance functions similarly to the acid-resistant coating found on pills, preventing stomach acid from destroying it. Instead, this novel coating envelops individual insulin molecules, serving as a "nanocarrier" that transports insulin molecules throughout the body to their targets.

Geographical Analysis

North America is expected to hold a significant position in the global nano-biotechnology market share

North America will likely account for a significant share of the global nano-biotechnology market, owing to its advanced research infrastructure, technological developments, collaborations, and recent launches and approvals. North America has emerged as a focus for advanced nanobiotechnology research owing to its many prestigious educational institutions and research facilities. This environment encourages cooperation between industry and academics, which results in the development of novel uses of nanotechnology in medicine, diagnostics, and healthcare.

For instance, in March 2024, a research team created a DNA origami platform DoriVac, whose core component is a self-assembling square block-shaped nanostructure. To one face of the square block, defined numbers of adjuvant molecules can be attached in highly tunable, nanoprecise patterns, while the opposite face can bind tumor antigens. In a new study, DoriVac vaccines enabled tumor-bearing mice to better control the growth of tumors and to survive significantly longer than control mice. Importantly, the effects of DoriVac also synergized with those of immune checkpoint inhibitors, a highly successful immunotherapy already widely used in the clinic.

The strong cooperation between funding organizations and government agencies is another important component. Organizations like the National Institutes of Health (NIH) in the US offer significant funding for nanotechnology-related research projects. This funding helps turn scientific findings into useful applications in addition to supporting fundamental research. The market environment is further improved by the region's large pharmaceutical and biotechnology companies, which make major investments in nanobiotechnology to create novel medications and treatments that make use of nanoscale advancements.

In June 2024, the National Science Foundation announced that it is awarding $35 million to improve research infrastructure across the nation, including the funds to create the Mississippi Nano-bio ImmunoEngineering Consortium. That association, led by Ole Miss researchers, will help seven institutions across the state bolster their research and development in the field of nanobiotechnology. The foundation announced that ultimately, the goal is not only to do good research but to make Mississippi an ideal location for the industry. Nanobiotechnology is one of the fastest emerging fields of science and was valued at more than $100 billion in 2023.

Asia Pacific is growing at the fastest pace in the global nano-biotechnology market

The Asia Pacific region is emerging as the fastest-growing market for nano-biotechnology, owing to a combination of increasing healthcare needs, significant government initiatives, and a burgeoning biotechnology ecosystem. Leading nations in this expansion include China, India, and Japan, which are using nanotechnology advancements to enhance applications and medication development procedures. The region's adoption of nanotechnology advances is being further accelerated by the growing demand for personalized medical and advanced healthcare solutions.

For instance, in September 2024, MGI Tech Co., Ltd., a company committed to building core tools and technologies that drive innovation in life science, announced the global rights to commercialize and distribute the new sequencing products CycloneSEQ-WT02* and CycloneSEQ-WY01*. With applications in various genomics fields, CycloneSEQ technology combines a number of technological advancements, such as sophisticated protein engineering, a new flow cell architecture, and a state-of-the-art base-calling algorithm, to enable high sequencing throughput and accuracy. The organization is planning to expand our omics technologies portfolio by integrating CycloneSEQ nanopore sequencing with DNBSEQ sequencing technology.

Competitive Landscape

The major global players in the global nano-biotechnology market include Johnson & Johnson Services, Inc., Abbott, Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Danaher Corporation, Thermo Fisher Scientific Inc., Pfizer Inc., Nanonics Imaging Ltd., and Bruker among others.

Emerging Players

Sona Nanotech, Nanobiotix, and Nanoform among others

Key Developments

• In September 2024, NIAB scientists develop a diagnostic kit to detect antibiotics in food samples. The diagnostic kits developed to detect antimicrobial resistance mark a significant leap forward for food safety. The scientists also developed nano-mineral biocapsule which allows for the precise delivery of personalized nutrient materials, drugs, antibiotics, or other bioactive molecules.
• In December 2024, Mara Nanotech, a pioneer in STEM education, is thrilled to announce the launch of its innovative STEM Medical Science Kit on Kickstarter. Designed to make advanced nano-bio science accessible to learners of all ages, this hands-on educational tool bridges the gap between theoretical learning and real-world application. The STEM Medical Science Kit empowers students, educators, and hobbyists to explore cutting-edge concepts like nanotechnology, biotechnology, and medical science. The kit includes user-friendly materials, detailed guides, and experiments that simulate real-world applications, inspiring curiosity and fostering critical thinking.
• In September 2023, Imperial spinout SPARTA Biodiscovery was created to bring novel analytical methods to the development and production of nanoparticles used in advanced medicines. After a little over a year in operation, the company has now secured a 3.5-million-pound seed investment from industry partner Sartorius that will support the deployment of its system in a range of commercial settings.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global nano-biotechnology market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Nanosensor
• 3.2. Snippet by Nanodevice
• 3.3. Snippet by Application
• 3.4. Snippet by End-User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
  • 4.1.2. Increasing Adoption and Technological Advancements of Nanobiotechnology
  • 4.1.3. Restraints
  • 4.1.4. Stringent Regulatory Requirements
  • 4.1.5. Opportunity
  • 4.1.6. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Nanosensor

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nanosensor
  • 6.1.2. Market Attractiveness Index, By Nanosensor
• 6.2. Optical Nanosensor*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Chemical Nanosensor
• 6.4. Physical Nanosensor
• 6.5. Biosensors
• 6.6. Others

7. By Nanodevice

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nanodevice
  • 7.1.2. Market Attractiveness Index, By Nanodevice
• 7.2. Nanomanipulator*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Nanomechanical Test Instruments
• 7.4. Nanoscale Infrared Spectrometers
• 7.5. Others

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Drug Delivery*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Diagnostics
• 8.4. Imaging
• 8.5. Gene Delivery
• 8.6. Tissue Engineering
• 8.7. Others

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Pharmaceutical and Biopharmaceutical Companies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Academic and Research Laboratories
• 9.4. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nanosensor
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nanodevice
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. The U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nanosensor
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nanodevice
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. UK
    • 10.3.7.3. France
    • 10.3.7.4. Italy
    • 10.3.7.5. Spain
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nanosensor
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nanodevice
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nanosensor
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nanodevice
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nanosensor
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nanodevice
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Johnson & Johnson Services, Inc.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Abbott
• 12.3. Novartis AG
• 12.4. Merck & Co., Inc.
• 12.5. Bristol-Myers Squibb Company
• 12.6. Danaher Corporation
• 12.7. Thermo Fisher Scientific Inc.
• 12.8. Pfizer Inc.
• 12.9. Nanonics Imaging Ltd.
• 12.10. Bruker

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us